期刊文献+

紫杉醇联合静脉和腹腔灌注顺铂治疗晚期卵巢癌的临床评价 被引量:5

Effect of paclitaxel combined with vein and abdominal cavity perfusion of cisplatin in the treatment of advanced ovarian cancer
下载PDF
导出
摘要 目的评价紫杉醇联合静脉和腹腔灌注顺铂治疗晚期卵巢癌的疗效。方法 50例晚期卵巢癌肿瘤患者,随机分成治疗组(IP+IV组:静脉和腹腔运用顺铂联合紫杉醇静脉治疗双途径治疗)28例和对照组(IV组:顺铂联合紫杉醇单纯静脉治疗)22例。结果治疗组有效率85.7%,对照组有效率72.7%,差异具有统计学意义(P<0.05)。全身毒性反应主要为消化道反应、肾毒性、血液毒性和神经毒性,全身毒性治疗组较对照组略低。结论治疗组较对照组治疗晚期卵巢癌疗效更高,毒性反应可以耐受,腹腔化疗应用于晚期卵巢癌是一种合理而可行的治疗模式。 Objective To observe the effect of paclitaxel combined vein and abdominal cavity perfusion of cisplatin in the treatment of advanced ovarian cancer.Methods 50 cases of advanced ovarian cancer were treated, 28 patients received IP+IV regimen(CDDP intraperitoneal and iv+Taxol iv)and 22 patients received IV regimen(CDDP iv+Taxol iv).Results In IP+IV group,the response rate was 85.7%. In IV group the response rate was 72.7%. The efficacy was statistically significant (P〈0.05). The main systematic toxicity were gastrointestinal reaction, nephro-toxicity, myelo-suppression and neurotoxicity. The systematic toxicity of IV was a little more than IP+IV, but the local toxicity is on the contrary. The efficacy was not statistically significant(P&gt;0.05).Conclusion IP+IV regimen are more effective than IV regime to patients with advanced ovarian cancer. The toxicity can be tolerated. Intraperitoneal chemotherapy can be applied to advanced ovarian cancer.
出处 《中国现代药物应用》 2014年第9期6-8,共3页 Chinese Journal of Modern Drug Application
关键词 晚期卵巢癌 腹腔灌注化疗 静脉化疗 紫杉醇 顺铂 Advanced ovarian cancer Intraperitoneal chemotherapy Intravenous chemotherapy Paclitaxel Cisplatin
  • 相关文献

参考文献6

二级参考文献15

  • 1孙燕.肿瘤内科治疗的回顾、现状和进展[J].中国新药杂志,1996,5(4):241-244. 被引量:10
  • 2Fujiwara K,Armstrong D,Morgan M,et al.Principles and practice of intraperitoneal chemtherapy for ovarian cancer[J].Int J Gynecol Cancer,2007,17(1):1-20. 被引量:1
  • 3Hess LM,Alberts DS.The role of intraperitoneal therapy in advanced ovarian cancer[J].Oncology,2007,21(2):227-232. 被引量:1
  • 4Landrum LM,Gold MA,Moore KN,et al.Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer:a review of complications and completion rates[J].Gynecol Oncol,2008,108(2):342-347. 被引量:1
  • 5Runowicz CD.Intraperitoneal chemotherapy in ovarian cancer:an update[J].Cancer J,2008,14(1):7-9. 被引量:1
  • 6American College of Obstetricians and Gynecologists.ACOG Committee Opinion No.396.Intraperitoneal chemotherapy for ovarian cancer[J].Obstet Gynecol,2008,111(1):249-251. 被引量:1
  • 7Ozols RF,Yong RC.Chemotherapy of ovarian cancer[J].Sem Oncol,1991,18:222. 被引量:1
  • 8McGuire WP,Rowinsky EK.Old drugs revisited,new drugs,and experimental approaches in ovarian cancer therapy[J].Sem Oncol,1991,8:255. 被引量:1
  • 9MarkmanM,Hakes T,Reichman B,et al.Ifosfamide and mensa in previously treated advanced epithelial ovarian cancer:activity in platinum-resistant disease[J].J Clin Oncol,1992,10:243. 被引量:1
  • 10Tommy K,Ingrid K,Per N.et al.Volumetric and dosimetric evaluation of radiation treatment planning:radiation conformity index[J].Int J Radiat Oncol BiolPhys,1998,42(5):1169. 被引量:1

共引文献22

同被引文献51

  • 1舒进忠,谭诗生.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究[J].中国生化药物杂志,2014,34(2):130-132. 被引量:34
  • 2巴彩霞,王亚兰,韩爱玲,李丽清,云文秀.卡铂腹腔灌注联合多西紫杉醇全身化疗双途径治疗晚期卵巢癌[J].临床肿瘤学杂志,2007,12(2):140-141. 被引量:10
  • 3SIEGEL R, MA J,ZOU Z,et al. Cancer statistics, 2014 [J].CA Cancer J Clin, 2014,64(1) :9-29. 被引量:1
  • 4KIPPS E, TAN DS, KAYE SB. Meeting the challenge of ascitesin ovarian cancer: new avenues for therapy and research [J].Nat Kev Cancer, 2013,13(4):273-282. 被引量:1
  • 5QIAN X,QIN J, PAN S, et al. Maintenance therapy in ovariancancer with targeted agents improves PFS and OS : a systematicreview and meta-Analysis [J]. PLoS One, 2015,10 (9):e!39026. 被引量:1
  • 6FEIGENBERG T, CLARKE B, VIRTANEN C, et al. Molecularprofiling and clinical outcome of high-grade serous ovariancancer presenting with low-versus high-volume ascites [J].Biomed Res Int, 2014,2014(5):367103. 被引量:1
  • 7LANE D, MATTE I, GARDE-GRANGER P, etal. Inflammation-regulating factors in ascites as predictive biomarkers of drugresistance and progression-free survival in serous epithelialovarian cancers [J]. BMC Cancer, 2015,15(7) :492-503. 被引量:1
  • 8ELIT L, OLIVER TK, COVENS A, et al. Intraperitonealchemotherapy in the first-line treatment of women with stage IIIepithelial ovarian cancer : a systematic review with metaanalyses[J]. Cancer, 2007,109(4):692-702. 被引量:1
  • 9JAABACK K, JOHNSON N,LAWRIE TA. Intraperitonealchemotherapy for the initial management of primary epithelialovarian cancer [J]. Cochrane Database Syst Rev, 2011,11(11):CD005340. 被引量:1
  • 10MARKMAN M, BUNDY BN, ALBERTS DS, et al. Phase II1 trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose earboplatin followed by intravenous paclitaxel and intraperitoneal eisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oneology Group, Southwestern Oneology Group, and Eastern Cooperative Oneology Group [J]. J Clin Oneol, 2001,19(4) : 1001-1007. 被引量:1

引证文献5

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部